Bioxytran (BIXT) Emerging Growth Virtual Conference 78 summary

Key technology platforms and clinical progress

• Three platform technologies: broad-spectrum oral antiviral, universal oxygen carrier, and cancer metastasis treatment, all developed using AI.

• Oral galectin inhibitor achieved 100% viral reduction in seven days in clinical trials, neutralizing COVID-19, influenza, and RSV.

• Universal oxygen carrier targets stroke, dementia, sickle cell anemia, and can deliver oxygen through clots; animal studies show safety and efficacy.

• Cancer metastasis platform focuses on galectin inhibition to improve immunology treatment response rates.

• Active FDA IND for blood substitute; ready for healthy human trials pending funding.

Recent government engagement and funding outlook

• Product pipeline and data presented to BARDA, NIH, NIAID, DTRA, and DOD; strong interest in influenza and oxygen carrier platforms.

• BARDA meeting revealed significant non-dilutive funding opportunities, though application process will require substantial effort.

• BARDA and other agencies showed particular interest in Ebola solution potential.

• U.S.-based manufacturing and unencumbered intellectual property highlighted to support government partnership.

Scientific and clinical data highlights

• Galectin inhibitors disrupt viral entry by binding to the galectin fold, blocking cell attachment for multiple virus families.

• In vitro and animal studies show broad-spectrum antiviral activity, including against influenza, RSV, and Ebola.

• Universal oxygen carrier demonstrated improved oxygen delivery and survival in hemorrhagic and stroke animal models.

• Clinical trials for the oral antiviral showed 100% PCR negativity at day seven, with rapid symptom resolution and no viral rebound.

• Favorable safety profile observed in both preclinical and clinical studies.